Fluvastatin D6 sodium
(Synonyms: 氟伐他汀钠D6; XU 62-320 (D6)) 目录号 : GC36061An internal standard for the quantification of fluvastatin
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Fluvastatin-d6 is intended for use as an internal standard for the quantification of fluvastatin by GC- or LC-MS. Fluvastatin is an inhibitor of HMG-CoA reductase (Ki = 0.3 nM for the rat enzyme).1,2 It also inhibits the human cytochrome P450 (CYP) isoform CYP2C9 (IC50 = 100 nM).3 Fluvastatin inhibits oxidized LDL-induced ferroptosis and reverses oxidized LDL-induced decreases in glutathione peroxidase 4 (GPX4) and system Xc- cystine-glutamate antiporter levels in human umbilical vein endothelial cells (HUVECs).4 In vivo, fluvastatin (2 mg/kg per day) decreases serum cholesterol, triglyceride, and phospholipid levels, the formation of thiobarbituric acid-reactive substances (TBARS), and vascular angiotensin-converting enzyme (ACE) activity in rabbits fed a high-cholesterol diet.5 It increases survival in a mouse model of myocardial infarction when administered at a dose of 10 mg/kg per day.6 Formulations containing fluvastatin have been used in the treatment of hypercholesterolemia and the prevention of cardiovascular disease.
1.Istvan, E.S., and Deisenhofer, J.Structural mechanism for statin inhibition of HMG-CoA reductaseScience292(5519)1160-1164(2001) 2.Corsini, A., Maggi, F.M., and Catapano, A.L.Pharmacology of competitive inhibitors of HMG-CoA reductasePharmacol. Res.31(1)9-27(1995) 3.Transon, C., Leemann, T., and Dayer, P.In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitorsEur. J. Clin. Pharmacol.50(3)209-215(1996) 4.Li, Q., Liu, C., Deng, L., et al.Novel function of fluvastatin in attenuating oxidized low-density lipoprotein-induced endothelial cell ferroptosis in a glutathione peroxidase4- and cystine-glutamate antiporter-dependent mannerExp. Ther. Med.22(5)1275(2021) 5.Mitani, H., Bandoh, T., Ishikawa, J., et al.Inhibitory effects of fluvastatin, a new HMG-CoA reductase inhibitor, on the increase in vascular ACE activity in cholesterol-fed rabbitsBr. J. Pharmacol.119(6)1269-1275(1996) 6.Hayashidani, S., Tsutsui, H., Shiomi, T., et al.Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarctionCirculation105(7)868-873(2002)
Cas No. | SDF | ||
别名 | 氟伐他汀钠D6; XU 62-320 (D6) | ||
Canonical SMILES | O=C([O-])C[C@H](O)C[C@H](O)/C=C/C(N1C(C([2H])([2H])[2H])C([2H])([2H])[2H])=C(C2=CC=C(F)C=C2)C3=C1C=CC=C3.[Na+] | ||
分子式 | C24H19D6FNNaO4 | 分子量 | 439.48 |
溶解度 | Soluble in DMSO | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.2754 mL | 11.3771 mL | 22.7542 mL |
5 mM | 0.4551 mL | 2.2754 mL | 4.5508 mL |
10 mM | 0.2275 mL | 1.1377 mL | 2.2754 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。